Pacific Ebitda from 2010 to 2024

PACB Stock  USD 2.27  0.07  2.99%   
Pacific Biosciences' EBITDA is decreasing over the years with slightly volatile fluctuation. Overall, EBITDA is projected to go to about -263.4 M this year. From 2010 to 2024 Pacific Biosciences EBITDA quarterly data regression line had arithmetic mean of (119,122,260) and r-squared of  0.46. View All Fundamentals
 
EBITDA  
First Reported
2009-09-30
Previous Quarter
-155.5 M
Current Value
-41.1 M
Quarterly Volatility
24.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pacific Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacific Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 27.9 M, Interest Expense of 15.1 M or Total Revenue of 210.5 M, as well as many indicators such as Price To Sales Ratio of 11.79, Dividend Yield of 0.0 or PTB Ratio of 4.3. Pacific financial statements analysis is a perfect complement when working with Pacific Biosciences Valuation or Volatility modules.
  
Check out the analysis of Pacific Biosciences Correlation against competitors.

Latest Pacific Biosciences' Ebitda Growth Pattern

Below is the plot of the Ebitda of Pacific Biosciences of over the last few years. It is Pacific Biosciences' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacific Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Pacific Ebitda Regression Statistics

Arithmetic Mean(119,122,260)
Geometric Mean95,788,044
Coefficient Of Variation(84.01)
Mean Deviation79,627,715
Median(89,268,000)
Standard Deviation100,070,592
Sample Variance10014.1T
Range321.2M
R-Value(0.68)
Mean Square Error5812.5T
R-Squared0.46
Significance0.01
Slope(15,193,380)
Total Sum of Squares140197.7T

Pacific Ebitda History

2024-263.4 M
2023-277.3 M
2022-282.2 M
2021-250.8 M
202039 M
2019-99.5 M
2018-100.1 M

About Pacific Biosciences Financial Statements

Pacific Biosciences stakeholders use historical fundamental indicators, such as Pacific Biosciences' Ebitda, to determine how well the company is positioned to perform in the future. Although Pacific Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pacific Biosciences' assets and liabilities are reflected in the revenues and expenses on Pacific Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pacific Biosciences of. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-277.3 M-263.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:
Check out the analysis of Pacific Biosciences Correlation against competitors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.46)
Revenue Per Share
0.64
Quarterly Revenue Growth
(0.28)
Return On Assets
(0.11)
Return On Equity
(0.65)
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.